Favorable Immune Profile Linked to VT1021 Treatment Response in rGBM
Patients treated with VT1021 for recurrent glioblastoma were found to have immune markers associated with response to treatment in a phase 1/2 study.
Patients treated with VT1021 for recurrent glioblastoma were found to have immune markers associated with response to treatment in a phase 1/2 study.
RAG-01 has received an FDA fast track designation and is being investigated for the treatment of non-muscle invasive bladder cancer.
Binod Dhakal, MD, MS, discusses the basis of the FDA approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma that has been treated with at least…
During a Case-Based Roundtable® event, Jubilee Brown, MD, discussed the efficacy and safety data from the KEYNOTE-775/Study 309 trial of lenvatinib plus pembrolizumab in patients with…
Data from the phase 3 INAVO120 trial support the breakthrough therapy designation granted by the FDA to inavolisib, palbociclib, and fulvestrant for the treatment of…
During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article…
Trials in small cell lung cancer and non–small cell lung cancer are fueling excitement in the oncology community.
Immune checkpoint inhibitor-based treatment was equally effective as a frontline treatment for both Black and White patients with metastatic renal cell carcinoma in separate analyses.
Pembrolizumab with chemotherapy led to a positive trend in overall survival among patients with endometrial cancer.
A study found that a novel ointment improved symptoms in patients with cutaneous T-cell lymphoma. The treatment was well-tolerated with minimal adverse effects.
9MW2821 was granted an orphan drug designation from the FDA and is being evaluated for the potential treatment of esophageal cancer, as well as other…